Taurunum Medical Journal
Sign in
Issue image

More articles from Volume 31, Issue 2, 2015

Poređenje ishoda lečenja pacijenata podvrgnutih TUR sa pacijentima lečenim BCG imunoterapijom nakon TUR -preliminarni rezutati

Komparativna analiza položaja fiziološkog mirovanja mandibule kod jednojajčanih blizanaca

Investigation of motivation for providing support to children with malignant diseases

Analysis Identification of Victims of Mass Catastrophe in Forensic Dentistry

Antiseptics and disinfectants in health care institutions: modern principles of application

Article views


{{ submission.title }}

Poređenje ishoda lečenja pacijenata podvrgnutih TUR sa pacijentima lečenim BCG imunoterapijom nakon TUR -preliminarni rezutati

Perica Jockic ,
Perica Jockic
View authors publications

Search this author on:

PubMed | Google Scholar
Nikola Kolarevic ,
Nikola Kolarevic
View authors publications

Search this author on:

PubMed | Google Scholar
Dragan Grebenarovic ,
Dragan Grebenarovic
View authors publications

Search this author on:

PubMed | Google Scholar
Sasa Mazibrada ,
Sasa Mazibrada
View authors publications

Search this author on:

PubMed | Google Scholar
Bora Cvetkovic ,
Bora Cvetkovic
View authors publications

Search this author on:

PubMed | Google Scholar
Aleksandar Argirovic ,
Aleksandar Argirovic
View authors publications

Search this author on:

PubMed | Google Scholar
Aleksandar Antic ,
Aleksandar Antic
View authors publications

Search this author on:

PubMed | Google Scholar
Goran Potpara ,
Goran Potpara
View authors publications

Search this author on:

PubMed | Google Scholar
Milenko Stanic ,
Milenko Stanic
View authors publications

Search this author on:

PubMed | Google Scholar
Vuk Aleksic
Vuk Aleksic
View authors publications

Search this author on:

PubMed | Google Scholar

Published: 01.12.2014.

Biochemistry

Volume 31, Issue 2 (2015)

pp. 1293-1298;

https://doi.org/10.5937/matmed1502293j

Abstract

Karcinom mokraćne bešike predstavlja načešći malignitet urinarnog trakta. Primarni standardni tretman tumora mokraćne bešike je transuretralna resekcija (TUR), ali procenat recidiva kod pacijenata tretiranih samo TUR-om je do 70%, a procenat progresije tumora tj, invazije u mišićni sloj je oko 30%, a to su pacijenti kojima je indikovano radikalno operativno lečenje. Intravezikalna instalacija bacillus Calmette-Guerin (BCG) nakon TUR tumora mokraćne bešike predstavlja dokazano najefikasnije pomoćno sredstvo u lečenju i profilaksi površinskih karcinoma mokraćne bešike. Cilj našeg rada je poređenje ishoda lečenja pacijenata podvrgnutih TUR sa pacijentima lečenim kombinovanom terapijom koja obuhvata sprovođenje imunoterapije intravezikalnom instalacijom BCG nakon TUR. Rezltati prikazani u radu predstavljaju izvod rezultata prospektivno-retrospektivne studije koja se od januara 2013. godine sprovodi na odeljenju Urologije KBC Zemun.

Keywords

karcinom mokraćne bešike,

bacillus Calmette-Guerin,

imunoterapija

References

1.
Anastasiadis A, De Reijke T. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv urol. 2012;(1):13–32.
2.
Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A, et al. Cancer statisics. CA Cancer J Clin. 2005;(1):10–30.
3.
Aldousari S, Kassouf W. Update on the management of non-muscle invasive baldder cancer. Can Urol Assoc J. 2010;(1):56–64.
4.
Nour H, Gobashy S, Kamal A, Elbaz A, Roshdy M, Kamel A. Low-dose bacilleCalmette-Guérin for nonmuscle-invasive bladder cancer: Results of a prospective study. Arab J Urol. 2015;(4):238–43.
5.
Sfakianos J, Shariat S, Favaretto R, Rioja J, Herr H. Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int. 2011;(4):526–30.
6.
Mohr D, Offord K, Owen R, Melton R. Asymptomatic microhematuria and urologic disease. A population based study. JAMA. 1986;224–9.
7.
Dershaw D, Panicek D. Imaging of invasive bladder cancer. Semin Oncol. 1990;544–50.
8.
Fuller S, J. Staging of advanced bladder cancer: current concepts and pitfalls. Urol Clin Corth Am. 1992;663–83.
9.
Brandau S, Suttman H. Thirty years of BCG immunotherapy for nonmuscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 2007;229–305.
10.
Gontero P, Bohle A, Malmstorm P, Donnell O, Oderda M, Dylvester M, et al. The role of bacillus Calmette-Guerin in the treatment of non musle invasive bladder cancer. 2010;410–29.

Citation

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Partners
TT Medik
Google Schoolar
DOAJ